88 related articles for article (PubMed ID: 17704748)
21. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study.
Dazzi C; Cariello A; Rosti G; Tienghi A; Molino A; Sabbatini R; Aieta M; Frassineti GL; Vertogen B; Giovanis P; Marangolo M
Haematologica; 2001 May; 86(5):523-9. PubMed ID: 11410417
[TBL] [Abstract][Full Text] [Related]
23. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
[TBL] [Abstract][Full Text] [Related]
24. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
[TBL] [Abstract][Full Text] [Related]
26. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
[TBL] [Abstract][Full Text] [Related]
27. Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer.
Wörmann B; Meden H; Riggert J; Humpe A; Wulf G; Koch B; Köhler M; Kuhn W; Hiddemann W
Anticancer Res; 1998; 18(3C):2237-41. PubMed ID: 9703793
[TBL] [Abstract][Full Text] [Related]
28. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
29. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
30. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
31. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F
Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592
[TBL] [Abstract][Full Text] [Related]
32. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer.
Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R
Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056
[TBL] [Abstract][Full Text] [Related]
34. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
36. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
Cottu PH; Extra JM; Espie M; Marolleau JP; de Roquancourt A; Makke J; Miclea JM; Laurence V; Mayeur D; Lerebours F; Cuvier C; Marty M
Br J Cancer; 2001 Nov; 85(9):1240-6. PubMed ID: 11720455
[TBL] [Abstract][Full Text] [Related]
37. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
[TBL] [Abstract][Full Text] [Related]
38. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
39. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer.
Brugger W; Fetscher S; Hasse J; Frommhold H; Pressler K; Mertelsmann R; Engelhardt R; Kanz L
Semin Oncol; 1998 Feb; 25(1 Suppl 2):42-8. PubMed ID: 9535211
[TBL] [Abstract][Full Text] [Related]
40. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]